Based on the icad inc stock forecast from 1 analysts, the average analyst target price for icad inc is USD 3.00 over the next 12 months. icad inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of icad inc is Bearish, which is based on 2 positive signals and 8 negative signals. At the last closing, icad inc’s stock price was USD 1.83. icad inc’s stock price has changed by -6.15% over the past week, +18.83% over the past month and +7.65% over the last year.
No recent analyst target price found for icad inc
No recent average analyst rating found for icad inc
Company Overview icad inc
iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire. Read Less
iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solut...Read More
Frequently Asked Questions About icad inc (ICAD) Stock
Based on ratings from 1 analysts icad inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on ICAD's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for ICAD is USD 3.00 over the next 12 months. The maximum analyst target price is USD 3 while the minimum anlayst target price is USD 3.
ICAD stock's Price/Earning ratio is 37.12.
Our analysis grades ICAD stock's Price / Earning ratio at F. This means that ICAD stock's Price/Earning ratio is above 56.00000000000001% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this ICAD may be a overvalued for its sector.
The last closing price of ICAD's stock was USD 1.83.
The most recent market capitalization for ICAD is USD 0.05B.
Based on targets from 1 analysts, the average taret price for ICAD is projected at USD 3.00 over the next 12 months.
This means that ICAD's stock price may go up by +63.93% over the next 12 months.
We can't find any ETFs which contains icad inc's stock.
As per our most recent records icad inc has 67 Employees.
icad inc's registered address is 98 Spit Brook Road, Nashua, NH, United States, 03062.
You can get more information about it from icad inc's website at https://www.icadmed.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About icad inc (ICAD) Stock
Based on ratings from 1 analysts icad inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on ICAD's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for ICAD is USD 3.00 over the next 12 months. The maximum analyst target price is USD 3 while the minimum anlayst target price is USD 3.
ICAD stock's Price/Earning ratio is 37.12.
Our analysis grades ICAD stock's Price / Earning ratio at F. This means that ICAD stock's Price/Earning ratio is above 56.00000000000001% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this ICAD may be a overvalued for its sector.
The last closing price of ICAD's stock was USD 1.83.
The most recent market capitalization for ICAD is USD 0.05B.
Based on targets from 1 analysts, the average taret price for ICAD is projected at USD 3.00 over the next 12 months.
This means that ICAD's stock price may go up by +63.93% over the next 12 months.
We can't find any ETFs which contains icad inc's stock.
As per our most recent records icad inc has 67 Employees.
icad inc's registered address is 98 Spit Brook Road, Nashua, NH, United States, 03062.
You can get more information about it from icad inc's website at https://www.icadmed.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ICAD !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
